PMID- 19166433
OWN - NLM
STAT- MEDLINE
DCOM- 20090417
LR  - 20211020
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 62
IP  - 12
DP  - 2008 Dec
TI  - The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of 
      gastro-oesophageal reflux disease following treatment with a full dose proton 
      pump inhibitor.
PG  - 1844-50
LID - 10.1111/j.1742-1241.2008.01923.x [doi]
AB  - BACKGROUND: Some patients with gastro-oesophageal reflux disease (GORD) remain 
      symptomatic despite proton pump inhibitor (PPI) treatment. There is a need to 
      determine the most appropriate management of these patients. AIMS: To assess the 
      effectiveness of esomeprazole 40 mg in GORD symptoms persisting in patients 
      receiving a full daily dose PPI. METHODS: In this multi-centre open label study 
      patients who had received full daily dose PPI for 8 weeks, but were still 
      experiencing persistent GORD symptoms, were treated with esomeprazole 40 mg for 8 
      weeks (n = 99). The primary outcome variable was the change in the frequency of 
      heartburn. Patient-reported outcomes were also assessed using the Reflux Disease 
      Questionnaire (RDQ) and the GORD Impact Scale (GIS). RESULTS: The mean frequency 
      of heartburn was reduced by 78% from 4.4 days a week to 1 day a week at the end 
      of the 8-week treatment period (p < 0.0001). Other GORD symptoms were also 
      significantly reduced following of treatment with esomeprazole (all p < 0.0001). 
      All RDQ dimensions and the level of symptom control as measured by the GIS also 
      showed significant improvement at 8 weeks. CONCLUSIONS: In patients with 
      persistent GORD symptoms despite full dose daily PPI therapy, esomeprazole 40 mg 
      significantly improved the frequency and severity of all GORD symptoms.
FAU - Jones, R
AU  - Jones R
AD  - Department of General Practice & Primary Care, King's College London, London, UK. 
      roger.jones@kcl.ac.uk
FAU - Patrikios, T
AU  - Patrikios T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - N3PA6559FT (Esomeprazole)
SB  - IM
EIN - Int J Clin Pract. 2009 Jun;63(6):977
MH  - Anti-Ulcer Agents/*administration & dosage
MH  - Chronic Disease
MH  - Esomeprazole/*administration & dosage
MH  - Female
MH  - Gastroesophageal Reflux/*drug therapy
MH  - Heartburn/prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Secondary Prevention
MH  - Treatment Outcome
PMC - PMC2680259
EDAT- 2009/01/27 09:00
MHDA- 2009/04/18 09:00
PMCR- 2009/05/11
CRDT- 2009/01/27 09:00
PHST- 2009/01/27 09:00 [entrez]
PHST- 2009/01/27 09:00 [pubmed]
PHST- 2009/04/18 09:00 [medline]
PHST- 2009/05/11 00:00 [pmc-release]
AID - IJCP1923 [pii]
AID - 10.1111/j.1742-1241.2008.01923.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2008 Dec;62(12):1844-50. doi: 10.1111/j.1742-1241.2008.01923.x.